GDTherapy

GDTherapy is a pre-clinical stage biotechnology company focused on developing novel, targeted therapeutics for glomerular diseases and chronic kidney disease. Founded by Dr. Sumant S. Chugh, the company's research centers on the role of Angiopoietin-like 4 (ANGPTL4) and sialylation pathways in the pathogenesis of nephrotic syndrome, minimal change disease (MCD), and diabetic nephropathy. GDTherapy is developing two primary therapeutic approaches: recombinant mutated human ANGPTL4 proteins designed to reduce proteinuria without causing hypertriglyceridemia, and sialylation-based therapeutics utilizing sialic acid precursors like N-acetyl-D-mannosamine (ManNAc) to restore proper protein sialylation in podocytes. The company holds exclusive rights to key patents developed in collaboration with the University of Alabama at Birmingham (UAB) Research Foundation.